Is this email not displaying correctly? View it in your browser.
Newswise - News for Journalists
Newswise Special Wire
Tuesday, December 6, 2016

Public edition |

Newswise Cancer Research Wire for 06-Dec-2016

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

UCLA Researchers Uncover New Evidence Linking Inflammation and Increased Prostate Cancer Risk

UCLA researchers have discovered a previously unrecognized type of progenitor cell that, though rare in most regions of the human prostate, is found in uncommonly high numbers in inflamed areas of the gland. These progenitor cells have the ability to...

– University of California, Los Angeles (UCLA), Health Sciences

Embargo expired on 06-Dec-2016 at 12:00 ET

Research: Indoor Tanning Age Restriction Could Reduce Melanoma Incidence

An age restriction on indoor tanning could save thousands of lives and millions of dollars, according to new research published online in the Journal of the American Academy of Dermatology....

– American Academy of Dermatology

Journal of the American Academy of Dermatology, Dec-2016

Researchers Discover a New Gatekeeper Role for Thymic Dendritic Cells in Controlling T Cell Release into the Bloodstream

A team of scientists led by Julie Saba, MD, PhD at UCSF Benioff Children’s Hospital Oakland, has unveiled a novel role of thymic dendritic cells, which could result in new strategies to treat conditions such as autoimmune diseases, immune deficienc...

– UCSF Benioff Children's Hospital Oakland

Journal of Experimental Medicine, October 17, 2016

Combination Immune Therapy Shows Promise Against Hodgkin Lymphoma

The combination of two new drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study. ...

– NYU Langone Medical Center

Embargo expired on 05-Dec-2016 at 19:30 ET

Advances in Multiple Myeloma, Lymphoma and Other Hematologic Malignancies Presented at Annual Meeting of American Society of Hematology

News release about significant new research findings in multiple myeloma, lymphoma and other hematologic disorders presented by researchers from University Hospitals Seidman Cancer Center and Case Western Reserve University School of Medicine at the ...

– University Hospitals Cleveland Medical Center

Embargo expired on 05-Dec-2016 at 20:45 ET

Immunotherapy Shows Promise in Preventing Leukemia Relapse

Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the 12 AML patients who received this experimental T-cell ...

– Fred Hutchinson Cancer Research Center

Juno Therapeutics, Inc.; National Institutes of Health

Embargo expired on 05-Dec-2016 at 18:45 ET

Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Yale Cancer Center team has evaluated the use of hypomethylating agents in patients suffering from Acute Myeloid Leukemia (AML) who were resistant to treatment with intensive chemotherapy. ...

– Yale Cancer Center

Embargo expired on 05-Dec-2016 at 19:30 ET

Nivolumab with Chemotherapy Improves Response, Survival in AML Study Patients

The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival in patients with acute myeloid leukemia (AML), according to preliminary findings by researchers at The Universit...

– University of Texas M. D. Anderson Cancer Center

Embargo expired on 05-Dec-2016 at 13:30 ET

Leukemia Drug Combo Is Encouraging in Early Phase I Clinical Trial

In a Phase I study, 8 out of 12 patients with relapsed and/or chemotherapy refractory blood cancers responded to a combination of the chemotherapy drugs thioguanine and decitabine; some of the responders had relapsed after treatment with decitabine a...

– Columbia University Medical Center

American Society of Hematology Annual Meeting

Moffitt Cancer Center Study Shows Promising Clinical Activity, Safety Results of KTE-C19 in Aggressive B-Cell Non-Hodgkin Lymphoma

TAMPA, Fla. – Immune cellular therapy is a promising new area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and kill cancer c...

– Moffitt Cancer Center

The Economic Burden of Treatment for Diffuse Large B-Cell Lymphoma

In a recent study, a Yale Cancer Center team confirmed expectations of higher healthcare utilization and costs with relapsed Diffuse Large B-Cell Lymphoma (DLBCL). ...

– Yale Cancer Center

Immune System, Unleashed by Cancer Therapies, Can Attack Organs

Doctors at Yale believe immunotherapy is causing a new type of acute-onset diabetes, with at least 17 cases so far. ...

– Yale Cancer Center

Pathway Linked to Slower Aging Also Fuels Brain Cancer

A metabolic pathway linked to slower aging is overactive in a deadly form of brain cancer, according to researchers at Washington University School of Medicine in St. Louis. Their findings suggest that tweaking the pathway to treat cancer may affect ...

– Washington University in St. Louis

Proceedings of the National Academy of Sciences, Dec-2016; K08NS081105; P30 CA91842; UL1TR000448; P50 CA094056

Rainbow Babies & Children’s Experts to Present Pediatric Focused Data at 58th American Society of Hematology Annual Meeting

Ashish Gupta, MBBS, MPH, a pediatric hematology fellow, will share results from one of the largest quality controlled retrospective studies of children with acquired aplastic anemia. The data makes a compelling case for the pediatric hematology commu...

– University Hospitals Cleveland Medical Center

ASH Annual Meeting, Dec. 3-6, 2016

Embargo expired on 03-Dec-2016 at 17:30 ET

CD19-Targeting CAR T-Cell Immunotherapy Yields High Responses in Treatment-Resistant CLL

In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immu...

– Fred Hutchinson Cancer Research Center

NCI (National Cancer Institute) R01 CA136551; NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) P30 DK56465; NCI P30 CA15704; Life Science Discovery Fund...

Embargo expired on 03-Dec-2016 at 12:00 ET

In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia

A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials. Pediatric oncologists from Children’s Hospital of Philadelphia (CHOP) today reported new resu...

– Children's Hospital of Philadelphia

American Society of Hematology, annual meeting

Embargo expired on 03-Dec-2016 at 19:00 ET

Biomarker May Predict Which Formerly Treated Cancer Patients Will Develop Highly Fatal Form of Leukemia

Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-relate...

– University of Texas M. D. Anderson Cancer Center

Embargo expired on 03-Dec-2016 at 10:45 ET

Research Shows Patients Ineligible for Studies May Benefit From Trial Participation

Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, such as existing medical illnesses....

– University of Texas M. D. Anderson Cancer Center

Embargo expired on 03-Dec-2016 at 18:30 ET

CPX-351 Improves Survival Following Allogeneic Hematopoietic Cell Transplant in Older High-Risk Acute Myeloid Leukemia Patients, Says Moffitt Cancer Center Physician

Analysis of a phase 3 trial shows that older patients with high-risk or secondary AML, who received initial treatment with CPX-351, had improved survival following allogeneic hematopoietic cell transplant, when compared with patients who received sta...

– Moffitt Cancer Center

American Society of Hematology Conference Annual Meeting

Moffitt Cancer Center Study Shows Improved Response Rates in Myelodysplastic Syndromes Patients Treated with Lenalidomide and Epoetin Alpha

Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients with lower-risk MDS benefit from treatment with recom...

– Moffitt Cancer Center

American Society of Hematology Annual Meeting

Johns Hopkins Researchers Uncover More Genetic Links to Brain Cancer Cell Growth

Two recently discovered genetic differences between brain cancer cells and normal tissue cells — an altered gene and a snippet of noncoding genetic material — could offer clues to tumor behavior and potential new targets for therapy, Johns Hopkin...

– Johns Hopkins Medicine

Acta Neuropathologica; Modern Pathology,

Treatment Significantly Reduces Chemotherapy-Induced Hearing Loss in Children

Investigators from Children’s Hospital Los Angeles and 37 other Children’s Oncology Group hospitals in the U.S. and Canada have determined that sodium thiosulfate prevents cisplatin-induced hearing loss in children and adolescents with cancer. Re...

– Childrens Hospital Los Angeles

Lancet Oncology, Dec 2016

New Drug for Patients with Late-Stage Lung Cancer

A new drug has been approved by the FDA in the fight against lung cancer. Tecentriq is being used by patients like Cornelius Bresnan, who had late-stage cancer....

– Yale Cancer Center

How Does an Elite Athlete Stay Fit During Breast Cancer Treatment?

Latest Research Highlights from ACSM...

– American College of Sports Medicine (ACSM)

American Cancer Society Approves New Research and Training Grants at Yale University

The American Cancer Society (ACS), the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding for three new research grants totaling over $1.7 million to investigators at Yale University....

– Yale Cancer Center

Penn Medicine and Children's Hospital of Philadelphia Researchers to Present Findings of Personalized Cellular Therapies

Researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children’s Hospital of Philadelphia (CHOP) will present the latest advances from their studies of personalized cellular therapies for blood cancers during th...

– Perelman School of Medicine at the University of Pennsylvania

Mount Sinai Health System Researchers Present Influential Research at ASH 2016

Mount Sinai Health System experts are available for interview at the American Society of Hematology meeting. ...

Expert Available

– Mount Sinai Health System

Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity

Previous studies identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, but new research led by University of California San Diego School of Medicine scientists reveals a surprising role for these enzymes in subduing cancer immunity. The...

– University of California San Diego Health Sciences


Embargo expired on 01-Dec-2016 at 12:00 ET

Disabling Critical "Node" Revs Up Attack When Cancer Immunotherapies Fall Short

PHILADELPHIA—An existing drug known as a JAK inhibitor may help patients who don’t respond to the so-called checkpoint inhibitor immunotherapy drugs overcome that resistance, suggests a new preclinical study published online in Cell today by Penn...

– Perelman School of Medicine at the University of Pennsylvania

P30CA016520; R01CA163739; R01CA158186; R01CA172651; U19AI082630; R01AI105343; U01AI095608; P01AI112521; W81XWH-09-1-0339; P50CA174523...

URI Scientist: Rare Childhood Disease Linked to Major Cancer Gene

Research team has discovered an important molecular link between a rare childhood genetic disease and a major cancer gene. The discovery could lead to improved treatment outcomes for some cancer patients....

– University of Rhode Island

Mayo Clinic Monthly News Tips — November 2016

Mayo Clinic Monthly News Tips — November 2016 ...

– Mayo Clinic

Journal of Alzheimer's Disease ; Journal of Clinical Oncology

New Imaging Method Can Detect, Monitor and Guide Treatment For, Prostate Cancer

An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. ...

– Johns Hopkins Medicine

Science Translational Medicine; P30CA008748, P30CA006973, P30CA008748-48, S10RR020892-01, S10RR028889-01, R33CA127768-02, P50-CA86438, 5R25CA096945-07, P50-CA08

Embargo expired on 30-Nov-2016 at 14:00 ET

A Receptor Discovered for Progranulin

Researchers at Thomas Jefferson University’s Sidney Kimmel Cancer Center discovered a cell-surface receptor highly expressed by cancerous and brain cells that directly and tightly binds progranulin. Importantly, the researchers also showed that thi...

– Thomas Jefferson University

Journal of Cell Biology; RO1 CA39481; RO1 CA47282; RO1 CA164462; T32 AR060715-04

Embargo expired on 30-Nov-2016 at 09:05 ET

Treatment Combination to Improve Survival in HER2-Negative Metastatic Breast Cancer

The study, “A Real-World Multicentre Retrospective Observational Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line Treatment for HER2-Negative Metastatic Breast Cancer,” was recently published in the Journal of Cell Physiology...

– Sbarro Health Research Organization (SHRO)

Journal of Cell Physiology

Mount Sinai Surgeons Remove Thyroid Gland Through Hidden Incision Underneath the Lip

A team of surgeons at Mount Sinai Beth Israel have performed the first endoscopic transoral thyroidectomy in New York, and one of the first of its kind in the nation. ...

– Mount Sinai Health System

Surgical Endoscopy

AACI Commends House Passage of Revised 21st Century Cures Act

The U.S. House of Representatives on Wednesday passed a revised version of the 21st Century Cures Act. The bill including $1.8 billion for cancer research....

– Association of American Cancer Institutes (AACI)

Mount Sinai Health System Launches DigniCap Scalp Cooling System for Women with Breast Cancer

The Mount Sinai Health System (MSHS) announced the launch of the DigniCap® scalp cooling system, which was recently cleared by the U.S. Food and Drug Administration (FDA) to reduce the likelihood of chemotherapy-induced hair loss in women with breas...

– Mount Sinai Health System

Cancer Risks in Blacks: 'A Complex, Entangled Web', Many Primary Care Doctors Are Reluctant to Talk About Medical Errors, Can Microbiome Influence Treatment Response, and More in the Cancer News Source

Click here to go directly to the Cancer News Source...

– Newswise

In One-Two Punch, Researchers Load 'Nanocarriers' to Deliver Cancer-Fighting Drugs and Imaging Molecules to Tumors

In a paper published in the journal Small, scientists at the University of Washington describe a new system to encase chemotherapy drugs within tiny, synthetic "nanocarrier" packages, which could be injected into patients and disassembled at the tumo...

– University of Washington

Journal Small

Discovery by NUS Researchers Suggests New Possibility in Treating Aggressive Ovarian Cancer

A study led by Dr Ruby Huang, Principal Investigator at Cancer Science Institute of Singapore at the National University of Singapore, has identified a molecule called AXL which is found to trigger the spread of an aggressive form of ovarian cancer c...

– National University of Singapore

Science Signaling

Indiana State Professors Use Survey to Assess HPV Knowledge, Develop Educational Initiatives

With a passion to advance the HPV conversation to include research related to HPV epidemiology, transmission and inclusion of oropharyngeal and other HPV-associated cancers, Professors Whitney Blondeau has teamed up with Olabode Ayodele to raise awar...

– Indiana State University


Cancer Research Institute and Fibrolamellar Cancer Foundation Announce Partnership to Fund Cancer Immunotherapy Research in Ultra-Rare Liver Cancer

Two nonprofits team up to fund immunotherapy research designed to benefit patients with an ultra-rare form of liver cancer....

– Cancer Research Institute

Largest Individual Gift in Henry Ford History Names New Detroit Cancer Building, Advances Cancer Research

Detroit businessman and philanthropist Mort Harris has given Henry Ford Health System the largest individual gift in its 100-year history to facilitate cancer clinical care and research in Detroit in honor of his late wife Brigitte Harris. ...

– Henry Ford Health System

UAMS Myeloma Institute Collaborates to Compile High-Quality Genetic Data

The University of Arkansas for Medical Sciences (UAMS) is collaborating with Dana-Farber Cancer Institute and Celgene Corp. to compile the largest set of high-quality ...

– University of Arkansas for Medical Sciences

AbbVie and Johns Hopkins to Collaborate on Cancer Research

North Chicago, Ill. and Baltimore, Md. December 5, 2016 – AbbVie (NYSE: ABBV), a global biopharmaceutical company, and the Johns Hopkins University School of Medicine today announced that they signed a five-year collaboration agreement with the goa...

– Johns Hopkins Medicine

Childhood Cancer Leader Joins MD Anderson to Lead Pediatrics

Richard Gorlick, M.D., an internationally recognized expert in pediatric oncology and hematology, today joined The University of Texas MD Anderson Children’s Cancer Hospital as the division head and department chair of Pediatrics. ...

– University of Texas M. D. Anderson Cancer Center

Embargo expired on 05-Dec-2016 at 10:15 ET

The Princess Margaret Cancer Foundation Selected as Top 10 Most Admired Corporate Cultures in Canada for 3rd Time

The Princess Margaret Cancer Foundation is thrilled to be selected as one of Canada’s 10 Most Admired Corporate Cultures in the Broader Public Service category....

– University Health Network (UHN)

Johns Hopkins Kimmel Cancer Center Expands Cancer Care and Research Facility at Sibley Memorial Hospital in Washington, D.C.

Cancer experts from the Johns Hopkins Kimmel Cancer Center are now embedded in a newly expanded facility within Johns Hopkins Medicine-owned Sibley Memorial Hospital in northwest Washington, D.C....

– Johns Hopkins Medicine

Parker Institute for Cancer Immunotherapy and Cancer Research Institute Launch Collaboration on Cancer Neoantigens

New collaboration between two nonprofits focused on cancer immunotherapy aims to identify new DNA-based targets for personalized cancer treatments ...

– Cancer Research Institute

Monell Center Receives Funding to Develop Technologies to Improve Taste of Lifesaving Drugs

The Monell Center announced today that it has received a $345,000 grant from the Bill & Melinda Gates Foundation. The grant supports an innovative global health research project titled, "Developing Novel Pediatric Formulation Technologies for Global ...

– Monell Chemical Senses Center

Higher Education Events

Improving the Utility of Value Tools in Cancer Care for Patients

NCCN will host its annual patient advocacy summit on December 9 in Washington, DC to explore gaps in current value tools, as well as patient definitions of value....

– National Comprehensive Cancer Network® (NCCN®)

Expert Pitch

City of Hope Experts Can Discuss ASH Studies on Blood Cancers

– City of Hope

Children’s Hospital Los Angeles Experts at ASH 2016

– Childrens Hospital Los Angeles





 Edit My Preferences
 Contact Us
 Newswise Home
 Newswise Contact Directory
 Expert Queries
 Presspass Application

More News from:


 University of California San Diego Health Sciences

 University of Texas M. D. Anderson Cancer Center

 Columbia University Medical Center

 University of Michigan Health System

 University of California, Los Angeles (UCLA), Health Sciences

 Washington University in St. Louis

Subscribe / Unsubscribe
Edit my preferences

© 2016 Newswise, Inc. All Rights Reserved.

215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417

 Contact Us